Shareholder update - year ended 31 December 2020
Filed with ASX · · 34 pages · English
The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (“Telix”) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinion
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Czech Republic Grants National Authorisation for TLX591 Kit
- Appendix 4C and Activities Report for December 2020 Quarter
- New Drug Submission filed with Health Canada for TLX591-CDx
- IP Agreement with U Southampton for access to TRALA data
- Telix Completes Acquisition of TheraPharm GmbH
Later from Telix Pharmaceuticals
- Appendix 4E - Results for announcement to the market
- S&P DJI Announces March 2021 Quarterly Rebalance
- TGA commences priority evaluation process for Illuccix
- Launch of International NOBLE Registry for SPECT Imaging
- Japanese Renal Cancer Imaging Trial Meets Study Objectives
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals